Overcoming adaptive therapy resistance in AML by targeting immune response pathways

Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent mechanisms, such as alternate activation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Transl Med
Hauptverfasser: Melgar, Katelyn, Walker, Morgan M., Jones, LaQuita M., Bolanos, Lyndsey C., Hueneman, Kathleen, Wunderlich, Mark, Jiang, Jiang-Kang, Wilson, Kelli M., Zhang, Xiaohu, Sutter, Patrick, Wang, Amy, Xu, Xin, Choi, Kwangmin, Tawa, Gregory, Lorimer, Donald, Abendroth, Jan, O’Brien, Eric, Hoyt, Scott B., Berman, Ellin, Famulare, Christopher A., Mulloy, James C., Levine, Ross L., Perentesis, John P., Thomas, Craig J., Starczynowski, Daniel T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985905/
https://ncbi.nlm.nih.gov/pubmed/31484791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaw8828
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge